Figitumumab (CP-751,871) Fact Sheet

COMPOUND DESCRIPTION	• Figitumumab (CP-751,871) is a selective fully human IgG2 monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R) pathway.
MECHANISM OF ACTION	• It is believed that by inhibiting the IGF-1 pathway, figitumumab may block one of the key signaling pathways in cancer cells that leads to uncontrolled proliferation and survival of tumor cells. Figitumumab is an investigational compound and part of Pfizer's signal transduction portfolio. • Signal transduction is the process by which a cell responds to substances in its environment. The binding of a substance to a molecule on the surface of a cell causes signals to be passed from one molecule to another inside the cell, and the signals can affect many functions of the cell. Cells with permanent changes in signal transduction molecules may develop into cancer.[1]
ABOUT IGF-1R	• The Insulin-like Growth Factor (IGF) pathway is a fundamental mechanism of cell survival. Activation of this pathway by the binding of the growth factor IGF-1 to IGF-1R triggers a complex signaling cascade that stimulates cell growth, proliferation and differentiation, and drives survival. • IGF-1R is often over-expressed in human tumors, including non-small cell lung cancer (NSCLC). It has been implicated in tumor cell proliferation, survival and chemotherapy resistance.[2]
CLINICAL STUDIES	• To date, clinical trial experience with figitumumab includes more than 1,000 patients in multiple tumor types. Currently, Pfizer is studying figitumumab in Phase II clinical trials for the treatment of prostate, breast and colorectal cancers and Ewing's sarcoma. • Based on the results of a Phase II study, Pfizer has initiated a Phase III clinical trial program for figitimumab in NSCLC, a disease with a significant unmet medical need. The NSCLC global program is a part of ADVIGO (ADVancing IGF-1R in Oncology). Following is a list of the ADVIGO trials that are currently open and enrolling: o ADVIGO 1016: Randomized, Open Label, Phase III Trial Of CP-751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non-Small Cell Lung Cancer[3] o ADVIGO 1018: Randomized, Open Label, Phase III Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non-Small Cell Lung Cancer Of Non Adenocarcinoma Histology[4]

For additional information, please visit: http://www.pfizer.com/asco.

[1] National Cancer Institute. Available at: http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=597170. Accessed 1-15-09

[2] Karp D. K., Paz-Ares G. L., Novello S., et al. Phase II Study of the Efficacy of the Anti-Insulin-like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination with Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer. Date TBD.

[3] Randomized, Open Label, Phase III Trial of CP- 751,871 in Combination with Paclitaxel and Carboplatin versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00596830?term=CP-751%2C871&phase=2&rank=2. Accessed April 27, 2009.

[4] ClinicalTrials.gov. Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With Cp 751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00673049?term=CP-751%2C871&phase=2&rank=1. Accessed April 27, 2009.

For additional information, please visit: http://www.pfizer.com/asco.